Skip to main content

Volume 18 Supplement 1

19th Annual SCMR Scientific Sessions

Prognostic implications of myocardial fibrosis and troponin levels measured by a highly sensitive assay in non-ischemic cardiomyopathy

Background

Myocardial replacement fibrosis detected as late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) and elevated serum cardiac troponin T levels measured with highly sensitive assays (hs-cTnT) have separately been shown to be associated with subsequent heart failure events in patients with non-ischemic cardiomyopathy (NICMP). Correlations between the two markers have also been reported, but limited data exist on the significance of elevated hs-cTnT levels and LGE presence in conjunction on heart failure events. We examined the association of these markers with heart failure outcomes in NICMP patients presenting to a tertiary center

Methods

Patients who presented for CMR between April 2008 and January 2012, received intravenous gadolinium, consented for blood draw, and were diagnosed with NICMP were included. Patients were excluded for any evidence of prior myocardial infarction, severe valvulopathy, cardiac mass, or infiltrative disorder. Cardiac parameters were abstracted from available CMR reports. Blood samples were measured with a highly sensitive assay using an automated platform (Cobas-e411 Troponin T hs, Roche Diagnostics). Subsequent hospitalization for decompensated heart failure, mechanical circulatory support, or heart transplant were abstracted from the available electronic health record (EHR). Deaths were abstracted from the EHR and the Social Security Death Index.

Results

Of 98 eligible patients, 74 had follow-up data available (median follow-up 2.3 [interquartile range (IQR) 0.9, 4.3] years) (Table 1). Over the interval period, there were 15 heart failure events (3 deaths, 13 heart failure hospitalizations). In patients without LGE, there was a trend toward an association between hs-cTnT and heart failure outcomes (p = 0.07) (Figure). In patients with LGE, there was a significant association between hs-cTnT and heart failure outcomes (p = 0.048) (Figure 1).

Table 1 Baseline characteristics, cardiac parameters derived from magnetic resonance imaging, and serum troponin levels.
Figure 1
figure1

Kaplan-Meier event-free survival estimates from heart failure events in non-ischemic cardiomyopathy patients in the absence (top panel) and presence (bottom panel) of myocardial fibrosis on delayed enhancement imaging. Each group of patients were sub-divided by tertiles of cardiac troponin T measured with a highly sensitive assay (hs-cTnT).

Conclusions

In patients with non-ischemic cardiomyopathy, cardiac troponin T levels measured with a highly sensitive assay are associated with heart failure outcomes in the presence of late gadolinium enhancement. These findings may support a strategy of combining LGE detection and hs-cTnT levels to risk-stratify further patients with non-ischemic cardiomyopathy.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Eric Y Yang.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, E.Y., Polsani, V., Brunner, G. et al. Prognostic implications of myocardial fibrosis and troponin levels measured by a highly sensitive assay in non-ischemic cardiomyopathy. J Cardiovasc Magn Reson 18, P121 (2016). https://doi.org/10.1186/1532-429X-18-S1-P121

Download citation

Keywords

  • Cardiac Magnetic Resonance
  • Late Gadolinium Enhancement
  • Electronic Health Record
  • Sensitive Assay
  • Cardiac Troponin